[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"immune-checkpoint-inhibitor-related-myocarditis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:immune-checkpoint-inhibitor-related-myocarditis":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,46,81],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100642535","ai-powered-ecg-analysis-for-deadly-arrhythmias-and-ici-myocarditis-100642535",false,"NCT07644715","AI-powered ECG Analysis for Deadly Arrhythmias and ICI Myocarditis","Efficient Deep Learning Approaches for the Rapid and Interpretable Detection of Deadly Arrhythmias in ECG Data","ELDORA","Inclusion Criteria:\n\n* subjects included in participating existing or ongoing ECG cohorts made available to ECGInsight\n* availability of ECG data (digital waveform or scanned\u002Fpaper ECG suitable for digitization) and relevant clinical\u002Fdemographic metadata\n* data use permitted by applicable ethical, regulatory, contractual and GDPR requirements.\n\nExclusion Criteria:\n\n* datasets or individual records for which required approvals, data-sharing agreements, de-identification\u002Fanonymization, or minimum ECG\u002Fmetadata quality requirements are not met. No interventional study treatment is assigned.",true,"ALL",{"count":20,"type":21},127000,"ESTIMATED","OBSERVATIONAL","ELDORA is a non-interventional observational data-science study aiming to develop and validate clinical-grade artificial intelligence tools applied to electrocardiogram (ECG) data. The project will standardize heterogeneous ECGs, create the ECGInsight harmonized database, and train interpretable models for life-threatening arrhythmia risk prediction, especially Torsades-de-Pointes\u002Flong QT syndrome and immune checkpoint inhibitor (ICI)-induced myocarditis. The project uses existing and ongoing national and international ECG cohorts with de-identified clinical metadata; AI outputs are intended for research\u002Fmodel development and are not used to drive patient care during the study.",[25,26,27],"Arrhythmia","Long QT Syndrome","Immune Checkpoint Inhibitor-Related Myocarditis",[29,30,31,32],"ECG","AI","Immune Checkpoint Inhibitors-Related Myocarditis","long QT","RECRUITING","2026-06-08",{"date":36,"type":37},"2026-06-12","ACTUAL",{"date":39,"type":37},"2026-01-01",{"date":41,"type":21},"2029-12-31",{"name":43,"class":44},"Groupe Hospitalier Pitie-Salpetriere","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":18,"minAge":53,"maxAge":4,"enrollmentInfo":54,"targetDuration":56,"studyType":22,"phases":4,"briefSummary":57,"conditions":58,"keywords":63,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":45},"100485269","global-cardio-oncology-registry-100485269","NCT05598879","Global Cardio Oncology Registry","G-COR","Inclusion Criteria:\n\n* New cardio-oncology consultation for breast cancer patients, or\n* New cardio-oncology consultation for Hodgkin's or non-Hodgkin's lymphoma patients, or\n* New cardio-oncology consultation for acute or chronic leukemia patients, or\n* New cardio-oncology consultation for multiple myeloma or AL amyloidosis, or\n* New cardio-oncology consultations for immune check-point inhibitors cardiac evaluation.\n* All patients have to be 18 years old or older\n\nExclusion Criteria:\n\n* Cardio-oncology patients who have previously had cardio-oncology evaluation and follow up by the investigators.\n* Minors less than 18 years old.\n* Inability or unwillingness to consent to participate","18 Years",{"count":55,"type":21},5000,"24 Months","G-COR is the first Global Prospective Cardio-Oncology Registry. It is a multinational, multicenter prospective observational cohort registry, with the goal of collecting clinical, laboratory, imaging, demographic, and socioeconomic data to identify risk factors associated with increased incidence of cancer therapy related cardiovascular toxicity (CTR-CVT) in different settings and to derive and validate risk scores for cardio oncology patients treated in different geographic locations throughout the world.",[59,60,27,61,62],"Breast Cancer","Hematologic Malignancy","Cardiotoxicity","Cardiovascular Diseases",[64,65,66,67,68,69,70,71],"cardiotoxicity","Cancer related cardiovascular diseases","prospective registry","international collaboration","social determinants of health","health care disparities","real world data","cardiology-oncology team work","2026-05-07",{"date":74,"type":37},"2026-05-12",{"date":76,"type":37},"2022-07-01",{"date":78,"type":21},"2029-07-01",{"name":80,"class":44},"The Cleveland Clinic",{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":4,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":18,"minAge":53,"maxAge":88,"enrollmentInfo":89,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":91,"conditions":92,"keywords":4,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":4},"100614378","monitoring-and-rehabilitation-for-iciaci-rehabilitationa-cohort-study-100614378","NCT07278817","Monitoring and Rehabilitation for ICIACI Rehabilitation：A Cohort Study","Study on the Monitoring of Traditional Chinese and Western Medicine Characteristics and Rehabilitation Program for ICIAM：A Cohort Study","Inclusion Criteria:\n\n* Aged 18 to 80 years, inclusive\n* Malignancy confirmed by cytology or histopathology\n* Diagnosis of ICIACI following ICI therapy\n* Assessed by the Multidisciplinary Team for Immune-Related Adverse Events as clinically recovered and entering the rehabilitation.\n\nExclusion Criteria:\n\n* Diagnosis of fulminant myocarditis or cardiac function of NYHA IV\n* Clear evidence suggesting cardiac injury not attributable to ICIs\n* Concurrent acute cardiovascular events or malignant arrhythmias\n* Coexisting severe immune-related adverse events affecting other organ systems\n* Associated severe systemic diseases, such as severe hepatic or renal insufficiency, or severe infection.","80 Years",{"count":90,"type":21},340,"Immune checkpoint inhibitor-associated cardiac injury (ICIACI) is a low-incidence but highly fatal adverse event. A significant knowledge gap exists regarding the disease characteristics and recovery status of patients during the ICIACI convalescent phase. The objectives of this study are to establish a national, multicenter cohort for this patient population and to comprehensively describe their clinical profiles from an integrated Traditional Chinese and Western medicine standpoint, as well as their current rehabilitation status.",[27],"NOT_YET_RECRUITING","2025-12-11",{"date":96,"type":37},"2025-12-12",{"date":98,"type":21},"2025-12-30",{"date":100,"type":21},"2028-07-31",{"name":102,"class":44},"China-Japan Friendship Hospital"]